Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Financial calendar
- March 16, 2022 - 2021 Fiscal Year Results
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 14, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Investor Relations Contact
Lucie Larguier, +33 (0)3 88 27 91 00
Key documents
Contact Relations Investisseurs
Lucie Larguier, +33 (0)3 88 27 91 00
Financial information
Key figures
| In € million except share and per share data | 2020 | 2019 | 2018 | 2017 | 2016 |
| Revenue | 9.9 | 13.7 | 42.9 | 8.1 | 10.3 |
| R&D Expense | 27.3 | -31.4 | -27.3 | -30.4 | -26.4 |
| G&A Expense | -6.5 | -7.1 | -7.0 | -5.7 | -6.2 |
| Net income (loss) | -17.2 | -18.8 | 8.0 | -32.3 | -25.2 |
| Net Cash Burn | -17.0 | -20.5 | -24.5 | -28.1 | -30.6 |
| Cash & Cash Equivalents | 26.3 | 43.3 | 16.9 | 41.4 | 56.2 |
| Earnings/Loss per Share (Basic and Diluted) | -0.21 | -0.23 | 0.13 | -0.52 | -0.45 |
| Shares Outstanding | 83,841,334 | 83,265,464 | 62,275,923 | 62,075,190 | 56,431,991 |
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
Chairman’s report on corporate governance and internal controls
Annual General Meeting information
- May 27, 2020 : Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment B) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 97,771,334 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech / CAC Mid 100 |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Bryan Garnier & Co. Ltd | Jean-Jacques Le Fur | jjlefur@bryangarnier.com | +33 (0)1 70 36 57 45 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Kepler Cheuvreux | Arsene Guekam Kepler’s research can be accessed here | aguekam@keplercheuvreux.com | +33 1 70 81 57 56 |
| Life Science Capital LLC | Jacques A. Villefranc | jacques@lifesciadvisors.com | +1 646 597-6997 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Webcasts
- December 15, 2021 - License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- March 11, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001 (in French)
- March 10, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001
- November 12, 2020 - Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
- July 22, 2020 - Results from Phase 1b/2 Study of TG4001 with Avelumab in Advanced HPV-Positive Cancers
- March 11, 2020 - Full Year Results 2019 & Business Update
- December 12, 2019 - Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
- September 18, 2019 - 2019 Half-Year Results and Business Update
- August 7, 2019 - Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
Financial calendar
- March 16, 2022 - 2021 Fiscal Year Results
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 14, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Investor events
- January 5, 2022 - 11th Annual LifeSci Advisors Corporate Access Event – Digital – January 5 to 7, 2022
- January 6, 2022 - 25th ODDO BHF Digital Forum – Digital – January 6, 7, 10 and 11, 2022
- January 10, 2022 - Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference – Digital – January 10 to 12, 2022
- January 17, 2022 - Biotech Showcase Investor Conference – Digital- January 17 to 19, 2022
- January 26, 2022 - Biomed Event – Paris
Annual General Meeting
Annual General Meeting of May 27,
2020 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 27 May 2021 à 10am behind closed doors Live broadcast (webcast)
Documents
- Notice of the 2020 General Shareholder’s Meeting (in French)
- Free translation of French BALO publication, including resolutions
- Ballot
- Information regarding the total number of the outstanding shares and voting rights of the company
- Universal Registration Document 2019
- Results of the vote (in French)
